<--- Back to Details
First PageDocument Content
Immunotherapy / Hematopoietic stem cell transplantation / Cytotoxic T cell / Leukemia / Philadelphia chromosome / Medicine / Biology / Immunology
Date: 2014-01-13 09:32:10
Immunotherapy
Hematopoietic stem cell transplantation
Cytotoxic T cell
Leukemia
Philadelphia chromosome
Medicine
Biology
Immunology

Synthetic Biology President’s Commission for the Study of Bioethical Issues  9 July 2010

Add to Reading List

Source URL: osp.od.nih.gov

Download Document from Source Website

File Size: 303,04 KB

Share Document on Facebook

Similar Documents

MDACC  LEUKEMIA AND LYMPHOMA Europe and the USA Linking Knowledge and Practice

MDACC LEUKEMIA AND LYMPHOMA Europe and the USA Linking Knowledge and Practice

DocID: 1vhjk - View Document

Genome-wide mapping of proviral integration sites in aggresive virus-induced leukemia Nicolas Rosewick1,2, Vincent Hahaut1, Maria Artesi1, Keith Durkin1, Ambroise Marçais3, Philip Griebel4, Natasa Arsic4, Véronique Ave

Genome-wide mapping of proviral integration sites in aggresive virus-induced leukemia Nicolas Rosewick1,2, Vincent Hahaut1, Maria Artesi1, Keith Durkin1, Ambroise Marçais3, Philip Griebel4, Natasa Arsic4, Véronique Ave

DocID: 1vcJH - View Document

Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Lijuan Xia, Duo Chen, Rui Han, et al. Mol Cancer Ther 2005;4:Updated version

Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Lijuan Xia, Duo Chen, Rui Han, et al. Mol Cancer Ther 2005;4:Updated version

DocID: 1v6bB - View Document

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model  Mouse-1 Mouse-2

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2

DocID: 1uSbg - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document